American Journal of Cardiology
Volume 103, Issue 8 , Pages 1113-1119 , 15 April 2009

Usefulness of Isosorbide Dinitrate and Hydralazine as Add-on Therapy in Patients Discharged for Advanced Decompensated Heart Failure

  • Wilfried Mullens, MD

      Affiliations

    • Department of Cardiology, Ziekenhuis Oost Limburg, Genk, Belgium
    • ,
  • Zuheir Abrahams, MD, PhD

      Affiliations

    • Department of Cardiovascular Medicine, Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio
    • ,
  • Gary S. Francis, MD

      Affiliations

    • Cardiovascular Diseases Division, University of Minnesota, Minneapolis, Minnesota
    • ,
  • George Sokos, DO

      Affiliations

    • Gerald McGinnis Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, Pennsylvania
    • ,
  • Randall C. Starling, MD, MPH

      Affiliations

    • Department of Cardiovascular Medicine, Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio
    • ,
  • James B. Young, MD

      Affiliations

    • Department of Cardiovascular Medicine, Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio
    • ,
  • David O. Taylor, MD

      Affiliations

    • Department of Cardiovascular Medicine, Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio
    • ,
  • W.H. Wilson Tang, MD

      Affiliations

    • Department of Cardiovascular Medicine, Kaufman Center for Heart Failure, Cleveland Clinic, Cleveland, Ohio
    • Corresponding Author InformationCorresponding author: Tel: 216-444-2121; fax: 216-445-6165

Received 16 October 2008 ,Revised 21 December 2008 ,Accepted 21 December 2008.

References 

  1. Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, et al Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study (V-HeFT). N Engl J Med. 1986;314:1547–1552
  2. Carson P, Ziesche S, Johnson G, Cohn JN. Racial differences in response to therapy for heart failure: analysis of the Vasodilator-Heart Failure Trials. J Card Fail. 1999;5:178–187
  3. Taylor AL, Ziesche S, Yancy C, Carson P, D'Agostino R, Ferdinand K, et al. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049–2057
  4. Heart Failure Society of America. Executive summary: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail. 2006;12:10–38
  5. Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult. Circulation. 2005;112(suppl):e154–e235
  6. Mullens W, Abrahams Z, Francis GS, Skouri HN, Starling RC, Young JB, et al. Sodium nitroprusside for advanced low-output heart. J Am Coll Cardiol. 2008;52:200–207
  7. Steimle AE, Stevenson LW, Chelimsky-Fallick C, Fonarow GC, Hamilton MA, Moriguchi JD, et al. Sustained hemodynamic efficacy of therapy tailored to reduce filling pressures in survivors with advanced heart failure. Circulation. 1997;96:1165–1172
  8. Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, et al A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303–310
  9. Tang WH, Vagelos RH, Yee YG, Benedict CR, Wilson K, Liss CL, et al. Neurohormonal and clinical response to high versus low dose enalapril therapy in chronic heart failure. J Am Coll Cardiol. 2002;39:70–78
  10. Dries DL, Exner DV, Gersh BJ, Cooper HA, Carson PE, Domanski MJ. Racial differences in the outcome of left ventricular dysfunction. N Engl J Med. 1999;340:609–616
  11. Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V, et al A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150:1707–1713
  12. Anand IS, Tam SW, Rector TS, Taylor AL, Sabolinski ML, Archambault WT, et al. Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial. J Am Coll Cardiol. 2007;49:32–39
  13. Cohn JN, Tam SW, Anand IS, Taylor AL, Sabolinski ML, Worcel M A-HeFT Investigators. Isosorbide dinitrate and hydralazine in a fixed-dose combination produces further regression of left ventricular remodeling in a well-treated black population with heart failure: results from A-HeFT. J Card Fail. 2007;13:331–339
  14. Taylor AL, Ziesche S, Yancy CW, Carson P, Ferdinand K, Taylor M, et al Early and sustained benefit on event-free survival and heart failure hospitalization from fixed-dose combination of isosorbide dinitrate/hydralazine: consistency across subgroups in the African-American Heart Failure Trial. Circulation. 2007;115:1747–1753
  15. Gogia H, Mehra A, Parikh S, Raman M, Ajit-Uppal J, Johnson JV, et al. Prevention of tolerance to hemodynamic effects of nitrates with concomitant use of hydralazine in patients with chronic heart failure. J Am Coll Cardiol. 1995;26:1575–1580
  16. Drexler H, Hayoz D, Münzel T, Hornig B, Just H, Brunner HR, et al. Endothelial function in chronic congestive heart failure. Am J Cardiol. 1992;69:1596-1501
  17. Dixon LJ, Morgan DR, Hughes SM, McGrath LT, El-Sherbeeny NA, Plumb RD, et al. Functional consequences of endothelial nitric oxide synthase uncoupling in congestive cardiac failure. Circulation. 2003;107:1725–1728
  18. Bauer JA, Fung HL. Concurrent hydralazine administration prevents nitroglycerine induced hemodynamic tolerance in experimental heart failure. Circulation. 1991;84:35–39
  19. Packer M, Le Jemtel TH. Physiologic and pharmacologic determinants of vasodilator response: a conceptual framework for rational drug therapy for chronic heart failure. Prog Cardiovasc Dis. 1982;24:275–292
  20. Gheorghiade M, Abraham WT, Albert NM, Greenberg BH, O'Connor CM, She L, et al. Systolic blood pressure at admission, clinical characteristics, and outcomes in patients hospitalized with acute heart failure. JAMA. 2006;296:2217–2226

 Dr. Tang is supported in part by the National Institutes of Health, National Center for Research Resources, CTSA 1UL1RR024989, Cleveland, Ohio.

PII: S0002-9149(09)00035-6

doi: 10.1016/j.amjcard.2008.12.028

American Journal of Cardiology
Volume 103, Issue 8 , Pages 1113-1119 , 15 April 2009

Article Tools

* Image Usage & Resolution